Skip to main content

Abstract

Objective:

Naltrexone, an efficacious medication for alcohol dependence, does not work for everyone. Symptoms such as insomnia and mood instability that are most evident during early abstinence might respond better to a different pharmacotherapy. Gabapentin may reduce these symptoms and help prevent early relapse. This clinical trial evaluated whether the combination of naltrexone and gabapentin was better than naltrexone alone and/or placebo during the early drinking cessation phase (first 6 weeks), and if so, whether this effect persisted.

Method:

A total of 150 alcohol-dependent individuals were randomly assigned to a 16-week course of naltrexone alone (50 mg/day [N=50]), naltrexone (50 mg/day) with gabapentin (up to 1,200 mg/day [N=50]) added for the first 6 weeks, or double placebo (N=50). All participants received medical management.

Results:

During the first 6 weeks, the naltrexone-gabapentin group had a longer interval to heavy drinking than the naltrexone-alone group, which had an interval similar to that of the placebo group; had fewer heavy drinking days than the naltrexone-alone group, which in turn had more than the placebo group; and had fewer drinks per drinking day than the naltrexone-alone group and the placebo group. These differences faded over the remaining weeks of the study. Poor sleep was associated with more drinking in the naltrexone-alone group but not in the naltrexone-gabapentin group, while a history of alcohol withdrawal was associated with better response in the naltrexone-gabapentin group.

Conclusions:

The addition of gabapentin to naltrexone improved drinking outcomes over naltrexone alone during the first 6 weeks after cessation of drinking. This effect did not endure after gabapentin was discontinued.

Formats available

You can view the full content in the following formats:

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 709 - 717
PubMed: 21454917

History

Received: 6 October 2010
Revision received: 5 January 2011
Accepted: 4 February 2011
Published online: 1 July 2011
Published in print: July 2011

Authors

Details

Raymond F. Anton, M.D.
From the Medical University of South Carolina, Institute of Psychiatry.
Hugh Myrick, M.D.
From the Medical University of South Carolina, Institute of Psychiatry.
Tara M. Wright, M.D.
From the Medical University of South Carolina, Institute of Psychiatry.
Patricia K. Latham, Ph.D.
From the Medical University of South Carolina, Institute of Psychiatry.
Alicia M. Baros, Ph.D.
From the Medical University of South Carolina, Institute of Psychiatry.
L. Randolph Waid, Ph.D.
From the Medical University of South Carolina, Institute of Psychiatry.
Patrick K. Randall, Ph.D.
From the Medical University of South Carolina, Institute of Psychiatry.

Notes

Address correspondence and reprint requests to Dr. Anton, Center for Drug and Alcohol Programs, Medical University of South Carolina, 67 President St., MSC 861, Charleston, SC 29425; [email protected] (e-mail).

Funding Information

Dr. Anton has received grant support or served as a consultant or on scientific advisory boards for Abbott Laboratories, Alkermes, Eli Lilly, GlaxoSmithKline, Hythiam, Johnson & Johnson, Lundbeck, Merck, Novartis, Organon, and Schering-Plough. Dr. Myrick has served on speakers bureaus for Bristol-Myers Squibb and Alkermes. The other authors report no financial relationships with commercial interests.Supported by National Institute on Alcohol Abuse and Alcoholism grants RO1 AA009568 and K05 AA017435.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share